Atara has granted Pierre Fabre the license to develop & commercialize Atara’s Ebvallo across the US & other global territories. Earlier, Pierre Fabre only had the rights to geographies incl. Europe, Middle East, Africa & other selected emerging markets
As per the extended agreement, Atara will receive an aggregate of $640M incl. $30M up front & is eligible to receive up to $610M in regulatory ($100M) & commercial ($510M) milestones, plus double-digit tiered royalties. Pierre Fabre will reimburse Atara for the expected global development costs of Ebvallo through BLA submission
Ebvallo is an allogeneic EBV-specific T-cell immunotherapy for EBV+ PTCL that has been approved in the EU & is marketed in Germany & Austria
Ref: PR Newswire | Image: Atara Biotherapeutics
Related Posts:- Atara Biotherapeutics Ebvallo (tabelecleucel) Receives EC’s Approval for Epstein‑Barr Virus Positive Post‑Transplant Lymphoproliferative Disease
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
